Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SeikagakuTSE:4548 73 EV-to-EBITDA is 6.49 as of Aug. 27, 2026, which is 40% below its 10-year median of 10.85. GuruFocus rates TSE:4548 with a GF Score™ of 73/100 and a GF Value™ of 円776.95 (Fairly Valued). The stock has 5 warning signs investors should review. Among 523 Medical Devices & Instruments companies, Seikagaku ranks better than 82.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Seikagaku's enterprise value is 円25,494 Mil.
Seikagaku's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円3,930 Mil. Therefore, Seikagaku's EV-to-EBITDA for today is 6.49.
The historical rank and industry rank for Seikagaku's EV-to-EBITDA or its related term are showing as below:
TSE:4548'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.92 Med: 10.85 Max: 63.97
Current: 6.48
During the past 13 years, the highest EV-to-EBITDA of Seikagaku was 63.97. The lowest was -5.92. And the median was 10.85.
TSE:4548's EV-to-EBITDA is ranked better than 82.03% of 523
companies
in the Medical Devices & Instruments industry
Industry Median: 14.59
vs TSE:4548: 6.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Seikagaku's share price for today is 円720.00.
Seikagaku's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円30.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Seikagaku's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4548 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Seikagaku's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seikagaku EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Seikagaku's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Seikagaku's EV-to-EBITDA falls into.
Seikagaku's current Enterprise Value is 円25,494 Mil.
Seikagaku's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3,930 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seikagaku (TSE:4548) has a EV-to-EBITDA of 6.49 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Seikagaku. This is 40% below median its historical median of 10.85. According to the industry distribution chart, Seikagaku ranks #94 out of 523 companies in the Medical Devices & Instruments industry, placing it in the top 18%.
Is Seikagaku's EV-to-EBITDA too high?
Seikagaku's current EV-to-EBITDA of 6.49 is 40% below median its 10-year median of 10.85. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.59. Seikagaku's value of 6.49 is 55.5% below this industry median. Based on the distribution chart, Seikagaku ranks #94 out of 523 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Seikagaku has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Seikagaku's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Seikagaku ranks #94 out of 523 companies for EV-to-EBITDA. This places Seikagaku in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.59. Seikagaku's value of 6.49 is 55.5% below this benchmark. While the company's 10-year median is 10.85 vs. the industry median of 14.59, Seikagaku has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.59, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seikagaku's current EV-to-EBITDA of 6.49 is 55.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Seikagaku. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seikagaku's current EV-to-EBITDA is 6.49, which is 40% below median its own 10-year median of 10.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seikagaku stock overvalued right now?
Based on GuruFocus' analysis, Seikagaku (TSE:4548) is currently considered Fairly Valued. The stock's GF Value™ is 円776.95, compared to a current price of 円720.00 — trading 7.3% below its estimated fair value. The current EV-to-EBITDA is 6.49, which is 40% below median its 10-year median of 10.85 and 55.5% below the Medical Devices & Instruments industry median of 14.59. Seikagaku's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Seikagaku (TSE:4548), the current EV-to-EBITDA is 6.49 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seikagaku (TSE:4548) Overvalued in 2026?
Based on GuruFocus' analysis, Seikagaku stock appears to be undervalued.
The current stock price of 円720.00 is trading 7.3% below its estimated GF Value™ of 円776.95.
GuruFocus considers Seikagaku to be Fairly Valued.
Key valuation signals for TSE:4548:
EV-to-EBITDA: 6.49 (40% below median its 10-year median of 10.85)
GF Value™: 円776.95 vs. price of 円720.00 (7.3% below fair value)
Industry Position: 55.5% below the Medical Devices & Instruments median (#94 of 523)
No single metric tells the full story. See the TSE:4548 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seikagaku Corp makes and sells pharmaceuticals and medical devices related to glycoconjugates. The firm operates in two segments: pharmaceutical and LAL. The pharmaceutical segment contributes the majority of revenue. This business sells pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates, as well as medical devices and bulk products. The LAL segment manufactures endotoxin-detecting reagents made from limulus amebocyte lysate that are used to control quality in the pharmaceutical manufacturing process. Seikagaku generates the majority of its sales in Japan.
73GF Score
Get the complete analysis for TSE:4548
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4548 has been successfully added to your 
